Neogen Corp stock (US6404911066): share jumps after strong quarterly update and integration progress
Neogen Corp's stock experienced a jump following a strong quarterly report that highlighted solid growth in food safety testing and significant progress in integrating the acquired 3M food safety business. The company's focus on food safety solutions and animal health products, alongside strategic acquisitions and ongoing innovation, are key drivers. Investors are closely watching the company's ability to convert revenue growth into sustained margin expansion as it continues to integrate the 3M assets and optimize its global footprint.
Neogen (NEOG) officer exercises 35,183 shares, settles tax with stock
Former Chief Legal Officer of Neogen (NEOG), Amy M. Rocklin, exercised 35,183 Restricted Stock Units, converting them into common stock at $9.29 per share. To cover tax obligations, 10,241 shares were withheld. Following these transactions, Rocklin directly holds 82,182 shares of NEOGEN CORP Common Stock.
Neogen Corp stock (US6404911066): integration progress and growth drivers in food and animal safety
Neogen Corp (NEOG) is actively integrating its acquired 3M food safety business, a process that brings both costs and revenue synergies. The company's core business revolves around food and animal safety diagnostics, with major revenue drivers including diagnostic kits, genomics services, and veterinary products. Neogen's growth is driven by increasing regulatory demands, consumer expectations for quality, and global trends in protein consumption and biosecurity.
Neogen Corp stock (US6404911066): what rising short interest means for investors
Neogen Corp (NEOG) shares have seen increased short interest, reaching over 5% of its free float, as the company continues to integrate its 3M acquisition and expand its product portfolio on Nasdaq. The company, a specialist in food and animal safety diagnostics, faces challenges from competition, integration of acquisitions, and the need for continuous innovation, despite benefiting from long-term regulatory and consumer trends in its markets. Investors are divided on the stock's near-term trajectory, with rising short interest signaling potential volatility or downside.
Clarkston Capital Group discloses 2.2M shares of Neogen (NEOG)
Clarkston Capital Group, along with Clarkston Capital Partners, LLC, Clarkston Companies, Inc., Jeffrey A. Hakala, and Gerald W. Hakala, has disclosed beneficial ownership of 2,204,788 shares of Neogen Corporation (NEOG). This represents a 1.01% stake in the company, based on 217,673,041 shares outstanding as of February 28, 2026. The shares are held in discretionary client accounts managed by Clarkston Capital Partners.
Neogen Corp stock (US6404911066): Recent 1.95% gain amid volatility
Neogen Corp (NEOG) shares recently gained 1.95% to $5.22 on July 25, 2025, extending a five-day winning streak despite a prior two-week loss, with analysts monitoring upcoming earnings on July 29, 2025. The company specializes in diagnostic test kits for food safety and animal health, serving vital roles in the US agriculture and food processing sectors. While showing short-term momentum, potential declines are forecasted ahead of the earnings report, highlighting market volatility.
Wall Street Zen Upgrades Neogen (NASDAQ:NEOG) to "Buy"
Wall Street Zen upgraded Neogen (NASDAQ:NEOG) to a "buy" rating from "hold" on Saturday. The upgrade comes after Neogen reported stronger-than-expected quarterly results, with EPS of $0.09 against estimates of $0.04 and revenue of $211.2 million, surpassing forecasts despite a 4.4% year-over-year decline. Institutional investors continue to hold a significant stake in Neogen, owning 96.73% of outstanding shares.
Do Neogen’s New Executive Equity Grants Reveal a Deeper Strategic Shift at NEOG?
Neogen's Chief Legal Officer recently received substantial equity grants, coinciding with the company facing declining sales, shrinking returns on capital, and ongoing EBITDA losses. While these grants don't immediately alter the investment narrative, they highlight the company's struggle to achieve sustainable cash generation amidst operational challenges. The key focus for investors remains on whether cost control and integration efforts can improve margins and alleviate financing concerns.
NEOGEN CORP (NEOG) officer exercises RSUs, uses shares for taxes
NEOGEN CORP's Chief Accounting Officer, John Patrick Moylan, reported exercising 4,558 Restricted Stock Units (RSUs) into common shares. Concurrently, 1,568 common shares were disposed of to cover tax obligations, not through an open-market sale. Following these transactions, Moylan directly holds 18,905 shares of NEOGEN common stock.
FY2026 Earnings Estimate for Neogen Issued By Zacks Research
Zacks Research has updated its earnings estimates for Neogen, raising the FY2026 EPS to $0.22 while simultaneously cutting near-term estimates and lowering FY2027/FY2028 forecasts, indicating a mixed outlook. Despite a recent earnings beat with $0.09 EPS on $211.2M revenue, the company experienced a 4.4% year-over-year revenue decline and a significant negative net margin. Neogen currently holds a "Hold" consensus rating with a target price of $10.67, trades around $9.09, and is largely institutionally owned (96.7%).
Neogen (NASDAQ: NEOG) awards shares and options to Chief Legal Officer
Neogen (NASDAQ: NEOG) Chief Legal Officer Stacey Jennifer Evans was granted 39,349 shares of common stock and 89,520 options to buy common stock on May 1, 2026. The shares were valued at $9.53 per share, and the options have an exercise price of $9.53 per share, expiring on May 1, 2036. Both the options and related RSUs will vest in equal annual installments over three years, indicating a multi-year compensation grant rather than an open-market transaction.
Neogen and Baxter Shares Are Falling, What You Need To Know
Shares of Neogen (NEOG) and Baxter (BAX) experienced declines following a renewed incident involving Iran and the UAE, which reignited concerns about input cost inflation and global supply chain disruptions for med-tech manufacturing due to rising crude oil prices. The medical device sector also faces increased freight costs and potential deferrals of elective procedures. Neogen shares fell 4.7% but are up 29.2% year-to-date, while Baxter shares dropped 3.2%.
Zacks Research Brokers Lower Earnings Estimates for Neogen
Zacks Research has updated its earnings estimates for Neogen (NASDAQ:NEOG), lowering the Q4 2026 EPS forecast from $0.07 to $0.03. This revision comes despite Neogen recently beating consensus earnings estimates for its latest quarter, reporting $0.09 EPS on $211.2 million revenue, though revenue marked a 4.4% year-over-year decline. The company currently holds an average "Hold" rating from analysts with an average price target of $10.67.
Vanguard Capital Management holds 11.16M shares in Neogen (NEOG)
Vanguard Capital Management has reported a beneficial ownership of 11.16 million shares in Neogen (NEOG), representing 5.13% of the company's common stock as of March 31, 2026. This disclosure was made through a Schedule 13G filing, indicating a passive investment. Vanguard holds sole voting power over approximately 1.6 million shares and sole dispositive power over all 11.16 million shares.
Vanguard Portfolio Management reports 12.9M Neogen shares (NEOG) on 13G
Vanguard Portfolio Management has reported a beneficial ownership of 12,916,330 shares of Neogen Corp (NEOG), representing 5.93% of the common stock as of March 31, 2026. This disclosure was made via a Schedule 13G filing, indicating a passive institutional stake. Vanguard maintains sole dispositive power over these shares, with a small portion having sole voting power, and affiliated investment vehicles exercise dispositive authority.
Neogen (NASDAQ:NEOG) Stock Crosses Above Two Hundred Day Moving Average - Should You Sell?
Neogen (NASDAQ:NEOG) stock recently crossed above its two hundred day moving average, with shares trading at $9.34. The company's latest quarterly results beat analyst estimates for EPS and revenue, but revenue was down year-over-year, and the company still faces profitability pressures with a negative net margin and P/E. Analysts currently have a consensus "Hold" rating on the stock with an average target price of $10.67, while institutional investors have actively bought and sold shares.
Is AOAC-Certified Rapid Listeria Test Altering The Investment Case For Neogen (NEOG)?
Neogen Corporation's new AOAC-certified rapid Listeria test could enhance its appeal to food manufacturers seeking faster contamination control. While this validation supports the demand for testing, the company's investment narrative still hinges on resolving integration issues, overcoming soft market conditions, and achieving profitability by 2029. Despite the positive news, analysts remain divided on the company's prospects, with some anticipating continued revenue decline and no profits until 2029.
NEOG Price Today: Neogen Corp. Stock Price, Quote & Chart | MEXC
This article provides the current stock price, key market data, and recent performance of Neogen Corp. (NEOG). It details how to buy NEOG stock on MEXC, describes the company's business in food and animal safety, and answers frequently asked questions about its financial metrics and market classification.
Neogen’s Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification
Neogen Corporation announced that its Molecular Detection Assay - Listeria Right Now™ rapid environmental monitoring test has received AOAC® Performance Tested Methods℠ (PTM) certification. This certification validates the test's performance for enrichment-free detection of viable and non-viable Listeria species on stainless steel surfaces. The technology aims to provide food manufacturers with a faster and more reliable method to identify contamination risks and strengthen their food safety programs.
Neogen (NEOG) Achieves Certification for Rapid Listeria Testing Method
Neogen Corp (NEOG) has successfully obtained AOAC Performance Tested Methods certification for its rapid Listeria testing assay, Listeria Right Now, designed for environmental monitoring on stainless steel surfaces. This certification represents a significant advancement in food safety, enabling quicker detection without traditional bacterial culture growth. Despite a strong GF Score™ of 74 indicating potential for long-term returns, the company faces challenges in revenue growth, although recent insider buying suggests confidence in its future performance.
Crude Oil Surges 3%; Neogen Shares Fall After Q3 Results
U.S. stocks saw broad gains with the Dow Jones, NASDAQ, and S&P 500 all trading higher. Neogen Corp shares fell by 3% despite beating Q3 earnings and sales estimates. Meanwhile, crude oil surged over 3%, and several other equities experienced significant movements based on company news and financial results.
Neogen’s Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification
Neogen Corporation announced its Molecular Detection Assay - Listeria Right Now™ rapid environmental monitoring test has received AOAC® Performance Tested Methods℠ (PTM) certification. This certification validates the test's performance for the enrichment-free detection of viable and non-viable Listeria species on stainless steel surfaces, offering a faster and more efficient method for food safety monitoring. The test provides actionable results in about two hours, enabling food manufacturers to quickly identify contamination risks and strengthen their environmental monitoring workflows.
Round Rock Advisors LLC Purchases 131,684 Shares of Neogen Corporation $NEOG
Round Rock Advisors LLC significantly increased its stake in Neogen Corporation (NASDAQ:NEOG) by 520.8% in the fourth quarter, purchasing an additional 131,684 shares to bring its total holding to 156,967 shares valued at approximately $1.10 million. Despite a consensus "Hold" rating from analysts, some firms have recently raised their price targets for Neogen. The company beat Q4 earnings estimates with $0.09 EPS and $211.2 million in revenue, though it reported a negative net margin of 69.93%.
Neogen Corp stock (US6404911066): Is its animal health focus strong enough to unlock new upside?
Neogen Corp (US6404911066) specializes in animal health and food safety diagnostics and genomics, addressing rising global food demands and agricultural pressures. The company's business model focuses on recurring revenue from diagnostic test kits and genomic tools, serving livestock production, food processing, and expanding into pet health and crop protection. Neogen's strategy aligns with precision agriculture and biosecurity needs, leveraging R&D, partnerships, and acquisitions to maintain a competitive edge despite competition from larger industry players.
Neogen Corporation 8-K SEC Filing April 20, 2026 – Key Entity Information, Trading Symbol, and Nasdaq Listing
Neogen Corporation filed an 8-K with the SEC on April 20, 2026, detailing investor facility tours and significant progress in its Petrifilm manufacturing. The company has completed operational qualifications for several Petrifilm single kit units and is advancing to performance qualifications, indicating enhanced production capabilities. This transparency aims to positively influence investor sentiment, with potential for share price impact upon successful validation.
Neogen (NEOG) plans investor tours to showcase Petrifilm validation progress
Neogen Corporation (NEOG) announced it will host two investor tours at its Petrifilm manufacturing facility in Lansing, Michigan, on April 20 and 21, 2026. The company will showcase progress on its Petrifilm validation efforts, specifically that it has successfully completed multiple operational qualifications for certain single kit units and is advancing to performance qualifications. This update was disclosed in an 8-K filing, detailing the technical validation and investor outreach plans.
Neogen schedules investor tours at Lansing facility, updates on Petrifilm validation By Investing.com
Neogen Corporation announced investor tours at its Lansing, Michigan Petrifilm manufacturing facility, scheduled for Monday and Tuesday. This announcement comes as Neogen's stock has seen a significant 117% surge over the last year. The company will also provide updates on the ongoing validation process for Petrifilm single kit units during these tours.
Neogen to host investor tours as Petrifilm SKUs complete operational qualifications
Neogen (NEOG) announced planned investor tours of its Lansing Petrifilm facility on April 20-21, 2026. The company also disclosed the completion of multiple operational qualifications for various Petrifilm single kit units (SKUs) and is moving forward with performance qualifications. This information will be shared with investors during the tours.
CapEx per share of Neogen Corp – FWB:NG2
This article provides financial data for Neogen Corp (FWB:NG2), specifically focusing on its CapEx per share. It presents a table showing the period, value, change, and percentage change for this metric, with data sourced from ICE Data Services and FactSet.
Neogen Reshapes Portfolio Around Food Safety With Divestitures And Job Cuts
Neogen is undergoing a significant portfolio reshaping, divesting its Genomics and Cleaners and Disinfectants businesses and reducing its global headcount by 10%. These actions aim to focus the company on its core Food Safety segment and streamline operations. Investors are encouraged to monitor how these changes impact future segment margins, free cash flow, and the company's path to profitability.
Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary
Neogen Corporation has announced the appointment of Jennifer Evans Stacey as its Chief Legal & Compliance Officer and Board Secretary. Stacey brings over 25 years of experience in legal and compliance roles, including more than 10 years as a public company chief legal and compliance officer in the life sciences industry. Her expertise is expected to support Neogen's strategies for organic and inorganic growth.
Neogen Corp. Opens with 5.61% Gain, Outperforming S&P 500's 2.51% Rise
Neogen Corp. (a small-cap pharmaceutical and biotechnology company) opened with a 5.61% gain, significantly outperforming the S&P 500's 2.51% rise. Despite a recent decline in pre-tax and net profits, the company has shown long-term growth with increasing net sales and strong institutional holdings. The stock exhibits a mixed technical picture but maintains a low debt-to-equity ratio, indicating financial stability.
Neogen Corporation (NASDAQ:NEOG) Q3 2026 Earnings Call Transcript
Neogen Corporation reported strong Q3 2026 earnings, beating expectations with an EPS of $0.09 against a forecast of $0.04. The company's Food Safety segment showed solid core growth of 4%, while the Animal Safety segment faced significant challenges due to supplier disruptions, impacting revenue. Neogen is implementing strategic initiatives focused on commercial prowess, high-impact innovation, and operational efficiency, including the in-sourcing of Petrifilm manufacturing and divesting its genomics business to strengthen its financial position and drive future growth.
Neogen: Fiscal Q3 Earnings Snapshot
Neogen Corp. reported a fiscal third-quarter loss of $17 million, or 8 cents per share, though its adjusted earnings reached 9 cents per share. The company's revenue of $211.2 million surpassed analyst expectations of $204.5 million. Neogen projects its full-year revenue to be between $857 million and $860 million.
Neogen Corp reports results for the quarter ended February 28 - Earnings Summary
Neogen Corp has released its earnings summary for the quarter that ended on February 28. This brief report, sourced from Reuters and Refinitiv, provides an overview of the company's financial performance for the period.
Neogen (NEOG) Q3 FY2026 Earnings: GAAP EPS -$0.08 misses -$0.05
Neogen (NEOG) reported its Q3 FY2026 earnings, with GAAP EPS of -$0.08 missing the -$0.05 estimate and revenue of $211.2 million also missing the $212.19 million estimate. While Food Safety revenue grew, Animal Safety declined due to supplier issues, and gross margin was impacted by Petrifilm transition costs. The company's balance sheet showed improvement with higher cash and reduced debt, and it announced an agreement to sell its global Genomics business to Zoetis Inc.
Neogen: Fiscal Q3 Earnings Snapshot
Neogen Corp. reported a fiscal third-quarter loss of $17 million, or 8 cents per share. Despite the loss, the company's revenue of $211.2 million surpassed analyst expectations of $204.5 million. Neogen (NEOG) anticipates full-year revenue to be between $857 million and $860 million.
Neogen Corp. Appoints Jennifer Evans Stacey As Chief Legal & Compliance Officer
Neogen Corp., a leader in food safety solutions, has appointed Jennifer Evans Stacey as its Chief Legal & Compliance Officer and Board Secretary. Stacey brings over 25 years of experience in the life sciences industry, including more than a decade as a public company chief legal and compliance officer. Her appointment is expected to support Neogen's growth initiatives and enhance its compliance framework.
Neogen: Fiscal Q3 Earnings Snapshot
Neogen Corp. reported a loss of $17 million, or 8 cents per share, in its fiscal third quarter. Adjusted earnings were 9 cents per share, and the company's revenue of $211.2 million surpassed Street forecasts, which anticipated $204.5 million. Neogen expects full-year revenue to be between $857 million and $860 million.
Neogen appoints Stacey as chief legal and compliance officer
Neogen Corp., a global leader in food safety solutions, has appointed Jennifer Evans Stacey as its new chief legal and compliance officer and board secretary. Stacey brings over 25 years of experience in the life sciences industry, including more than a decade as a public company chief legal and compliance officer. Her expertise is expected to support Neogen's growth initiatives, compliance framework, and long-term sustainability.
Neogen’s Recovery Hopes Versus Uncertain Performance: Is Fundamental Expansion Enough to Support the Surge?
Neogen's stock has surged 40.2% this year, nearing its 52-week peak, driven by investor optimism following leadership changes and debt reduction. Despite this rally, analysts remain cautious, setting a modest price target and highlighting concerns over persistent revenue decline and current net losses. The upcoming third-quarter earnings report will be crucial in determining if the company's core growth and profitability improvements can sustain its high valuation.
Neogen Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Neogen Corporation is set to release its third-quarter earnings on Thursday, April 9, with analysts predicting a dip in earnings per share and revenue compared to the previous year. Ahead of the announcement, several analysts have revised their price targets and ratings for NEOG, including Piper Sandler, Guggenheim, and CJS Securities. The company recently announced the sale of its Genomics business to Zoetis.
Neogen (NASDAQ:NEOG) Trading Up 3.8% - Time to Buy?
Neogen (NASDAQ:NEOG) saw its shares increase by 3.8% on Tuesday, though with thin trading volume. Analysts hold a mixed view on the stock, with an average "Hold" rating and a consensus price target of $10.67. Despite beating quarterly earnings and revenue estimates, the company continues to face profitability concerns, evidenced by a negative net margin and PE ratio.
Neogen Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Neogen Corporation (NASDAQ: NEOG) is set to release its third-quarter earnings on Thursday, April 9, with analysts forecasting a decrease in both earnings per share and revenue compared to the previous year. Ahead of the earnings call, several accurate analysts from firms like Piper Sandler, Guggenheim, and CJS Securities have revised their price targets and ratings for Neogen, reflecting varying sentiments on the company's stock. The company's shares recently closed at $9.56, rising after the announcement of its Genomics business sale to Zoetis.
Neogen Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Neogen Corporation (NASDAQ: NEOG) is set to release its third-quarter earnings before the market opens on Thursday, April 9. Analysts anticipate earnings of 5 cents per share on revenue of $204.62 million. Several analysts have recently updated their ratings and price targets for Neogen, with outcomes ranging from maintaining a Neutral rating to upgrading the stock.
Neogen’s Q3 Earnings Clouded by Regulatory Delays, Gross Margins Hold Strong
Neogen (NEOG) is projected to report Q3 2026 revenue of $215 million, a 4% year-over-year decline, with an expected net loss of $12 million due to regulatory scrutiny and delayed product approvals. Despite these headwinds and a downgraded rating from Jefferies, the company's gross margins remain strong, and Raymond James has upgraded Neogen to Market Outperformer due to robust demand in food safety diagnostics. Neogen is focusing on strategic expansion in Europe and R&D investment to mitigate regulatory challenges and diversify markets, offering cautious optimism for its longer-term prospects.
Countdown to Neogen (NEOG) Q3 Earnings: Wall Street Forecasts for Key Metrics
Wall Street analysts predict Neogen (NEOG) will report Q3 earnings of $0.04 per share, a 60% decline year-over-year, with revenues forecasted at $204.46 million, down 7.5%. The consensus EPS estimate has been revised downward by 8.3% in the last 30 days. Analysts have also provided detailed forecasts for various key metrics within Animal Safety and Food Safety divisions, with the stock currently holding a Zacks Rank #4 (Sell).
NEOG Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Neogen Corp (NEOG). It indicates a "Neutral" overall technical sentiment based on a proprietary analysis of 12 technical signals. The analysis details key indicators like RSI, MACD, support and resistance levels, and various moving averages to offer insights into NEOG's short-term momentum and long-term trends.
Neogen Leadership Change Puts Governance And Compliance Execution In Focus
Neogen (NasdaqGS:NEOG) has announced the departure of its Chief Legal and Administrative Officer, Amy Rocklin, effective March 31, 2026. This leadership change is significant due to Neogen's recent performance fluctuations and ongoing issues like labor actions and product quality concerns. Investors are advised to monitor the company's succession plan, shifts in compliance priorities, and how the board communicates around this transition, especially given the company's current unprofitability and integration challenges.
Neogen (NEOG) to Release Quarterly Earnings on Wednesday
Neogen (NASDAQ:NEOG) is scheduled to release its Q3 2026 earnings before the market opens on Wednesday, April 8th, with analysts forecasting an EPS of $0.04 and revenue of $204.615 million. The company's previous report showed an EPS beat but a negative net margin and a year-over-year revenue decline. The stock currently holds a consensus "Hold" rating with a target price of $10.67, and institutional investors own a significant portion of its shares.
